Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 699 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Optic Nerve Disease Clear all
Completed Phase 2 Interventional
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
GDNF & Synchro Med Infusion System
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced May 22, 2026, 12:00 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Leber's Hereditary Optic Neuropathy (LHON)
Interventions
Idebenone
Drug
Lead sponsor
Santhera Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
9
States / cities
Phoenix, Arizona • Palo Alto, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced May 22, 2026, 12:00 AM EDT
Completed Phase 4 Interventional
View directory record Official record
Conditions
Non Arteritic Ischemic Optic Neuropathy
Interventions
dalfampridine, Placebo
Drug
Lead sponsor
Neuro-Ophthalmologic Associates, PC
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2016 · Synced May 22, 2026, 12:00 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
Placebo, ABBV-8E12
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
27
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced May 22, 2026, 12:00 AM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced May 22, 2026, 12:00 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Uveal Melanoma, Liver Metastases
Interventions
GM-CSF, Embolization
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced May 22, 2026, 12:00 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Neutropenia, Sarcoma
Interventions
voriconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 11 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
Orange, California • San Diego, California • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced May 22, 2026, 12:00 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, ipilimumab, tyrosinase peptide, adjuvant therapy
Biological · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced May 22, 2026, 12:00 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Quisinostat
Drug
Lead sponsor
University of Miami
Other
Eligibility
19 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced May 22, 2026, 12:00 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Autoimmune Diseases, Dry Eye, Neurotrophic Keratitis
Interventions
Acthar Gel 80 UNT/ML Injectable Solution
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced May 22, 2026, 12:00 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Stage I Intraocular Melanoma, Stage IIA Intraocular Melanoma, Stage IIB Intraocular Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIB Intraocular Melanoma, Stage IIIC Intraocular Melanoma, Stage I Uveal Melanoma AJCC V7, Stage II Uveal Melanoma AJCC V7, Stage III Uveal Melanoma AJCC V7
Interventions
Sunitinib, Valproic Acid, Sunitinib Malate, Sunitinib Malate + Valproic Acid
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced May 22, 2026, 12:00 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
1,540 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2022
U.S. locations
3
States / cities
Birmingham, Alabama • La Jolla, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced May 22, 2026, 12:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Extraocular Retinoblastoma, Intraocular Retinoblastoma, Recurrent Retinoblastoma
Interventions
Laboratory Biomarker Analysis, Questionnaire Administration
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
49
States / cities
Los Angeles, California • Madera, California • San Francisco, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced May 22, 2026, 12:00 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
Nivolumab, Relatlimab
Drug
Lead sponsor
Jose Lutzky, MD
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced May 22, 2026, 12:00 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Vestibular Neuropathy
Interventions
Incremental Velocity Error (IVE), Traditional Vestibular Rehabilitation (VPT)
Device · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland • Fort Belvoir, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced May 22, 2026, 12:00 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Movement Disorder, Multiple System Atrophy, Parkinson's Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced May 22, 2026, 12:00 AM EDT
Terminated Not applicable Interventional Results available
View directory record Official record
Conditions
Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Subependymal Giant Cell Astrocytoma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Recurrent Adult Brain Tumor, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Diffuse Astrocytoma, Recurrent Childhood Fibrillary Astrocytoma, Recurrent Childhood Gemistocytic Astrocytoma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliomatosis Cerebri, Recurrent Childhood Gliosarcoma, Recurrent Childhood Oligoastrocytoma, Recurrent Childhood Oligodendroglioma, Recurrent Childhood Pilomyxoid Astrocytoma, Recurrent Childhood Protoplasmic Astrocytoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligoastrocytoma, Untreated Childhood Anaplastic Oligodendroglioma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Cerebellar Astrocytoma, Untreated Childhood Cerebral Astrocytoma, Untreated Childhood Diffuse Astrocytoma, Untreated Childhood Fibrillary Astrocytoma, Untreated Childhood Gemistocytic Astrocytoma, Untreated Childhood Giant Cell Glioblastoma, Untreated Childhood Glioblastoma, Untreated Childhood Gliomatosis Cerebri, Untreated Childhood Gliosarcoma, Untreated Childhood Oligoastrocytoma, Untreated Childhood Oligodendroglioma, Untreated Childhood Pilomyxoid Astrocytoma, Untreated Childhood Protoplasmic Astrocytoma, Untreated Childhood Subependymal Giant Cell Astrocytoma, Untreated Childhood Visual Pathway and Hypothalamic Glioma, Untreated Childhood Visual Pathway Glioma
Interventions
18F-fluoro-dihydroxyphenylalanine, Positron emission tomography (PET), Computed tomography (CT), Magnetic resonance imaging
Drug · Procedure
Lead sponsor
Erik Mittra
Other
Eligibility
16 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced May 22, 2026, 12:00 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Extra-adrenal Paraganglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Spinal Cord Neoplasm, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions
vorinostat, temozolomide, diagnostic laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
7
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced May 22, 2026, 12:00 AM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Bethesda, Maryland • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced May 22, 2026, 12:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Normal-Tension Glaucoma
Interventions
Sensimed Triggerfish, Blood Pressure
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced May 22, 2026, 12:00 AM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Uveal Melanoma
Interventions
PAC-1, Entrectinib
Drug
Lead sponsor
Arkadiusz Z. Dudek, MD
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced May 22, 2026, 12:00 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic, Uveal Melanoma, Recurrent, Eye Cancer, Intraocular Melanoma, Eye Cancer
Interventions
NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.
Drug
Lead sponsor
Novelwise Pharmaceutical Corporation
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Scottsdale, Arizona • Denver, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced May 22, 2026, 12:00 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Wolfram Syndrome
Interventions
AMX0035
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
17 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced May 22, 2026, 12:00 AM EDT
Not listed Phase 1 Interventional
View directory record Official record
Conditions
Retinoblastoma
Interventions
Episcleral Topotecan
Drug
Lead sponsor
Targeted Therapy Technologies, LLC
Industry
Eligibility
Up to 18 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced May 22, 2026, 12:00 AM EDT